PRINCETON, N.J. - PDS Biotechnology (NASDAQ:PDSB) Corporation (NASDAQ:PDSB), a clinical-stage biopharmaceutical company, has announced significant developments in its infectious disease vaccine platform, Infectimune®. The company's preclinical research, recently published in the journal Vaccines, indicates that its proprietary platform may enhance the effectiveness of influenza vaccines.
The study highlighted that Flublok®, an existing recombinant protein influenza vaccine, when combined with Infectimune® (R-DOTAP), produced a superior quantity and quality of multifunctional CD4 T cells compared to other infectious disease adjuvants. These findings suggest that Infectimune® could be a key component in the next generation of preventive vaccines, potentially offering broader protection against multiple flu strains.
Further bolstering PDS Biotech's position, the United States Patent and Trademark Office (USPTO) granted U.S. Patent Number 11,904,015 in February 2024. This patent is directed towards vaccine compositions that use the Infectimune® platform with influenza antigens to elicit both T cells and antibody responses. According to Dr. Frank Bedu-Addo, President and CEO of PDS Biotech, this patent enhances the company's intellectual property portfolio and is integral to their business strategy.
Infectimune® is currently being utilized in PDS0202, the company's universal influenza vaccine candidate. Preclinical research suggests that the vaccine candidate not only induces a robust immune response but also offers potential advantages over existing vaccines, including the ability to provide broad cross-protective immunity to different influenza subtypes.
PDS Biotech's broader pipeline includes targeted cancer immunotherapies and infectious disease vaccines based on their proprietary T cell-activating platforms. The company's Versamune® platform has shown promising results in activating effective tumor-attacking T cells, and their IL-12 fused antibody drug conjugate (PDS01ADC) is designed to target tumors and enhance T-cell activity.
This announcement is based on a press release statement from PDS Biotechnology Corporation. As PDS Biotech continues to advance its research and development, the company's focus remains on overcoming the limitations of current immunotherapy approaches and enhancing the efficacy of vaccines and treatments for infectious diseases and cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.